Revolution Medicines, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVMD research report →
Companywww.revmed.com
Revolution Medicines, Inc. , a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
- CEO
- Mark A. Goldsmith
- IPO
- 2020
- Employees
- 616
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $31.99B
- P/E
- -21.73
- P/S
- 0.00
- P/B
- 19.87
- EV/EBITDA
- -23.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -83.22%
- ROIC
- -70.02%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,131,301,000 · -88.52%
- EPS
- $-5.95 · -66.20%
- Op Income
- $-1,182,369,000
- FCF YoY
- -60.94%
Performance & Tape
- 52W High
- $155.70
- 52W Low
- $34.00
- 50D MA
- $122.37
- 200D MA
- $82.86
- Beta
- 1.41
- Avg Volume
- 2.97M
Get TickerSpark's AI analysis on RVMD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 26 | Mancini Anthony | other | 3,120 |
| Apr 27, 26 | Mancini Anthony | other | 3,120 |
| Apr 27, 26 | Mancini Anthony | sell | 1,671 |
| Apr 27, 26 | Mancini Anthony | sell | 1,049 |
| Apr 27, 26 | Mancini Anthony | sell | 400 |
| Apr 15, 26 | GOLDSMITH MARK A | other | 96,756 |
| Apr 15, 26 | GOLDSMITH MARK A | other | 96,756 |
| Apr 15, 26 | GOLDSMITH MARK A | other | 23,244 |
| Apr 15, 26 | GOLDSMITH MARK A | sell | 120,000 |
| Apr 15, 26 | GOLDSMITH MARK A | other | 23,244 |
Our RVMD Coverage
We haven't published any research on RVMD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RVMD Report →